BiotechTube
Rezon Bio

Rezon Bio

Warsaw, Poland· Est.
rezonbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Rezon Bio is a Polish CDMO founded in 2021, offering integrated biologics development and manufacturing services. With over 1,100 employees and facilities in Warsaw-Duchnice and Gdańsk, it provides scalable solutions from clinical to commercial scale, boasting a 95% batch success rate and regulatory approvals from major agencies like the FDA and EMA. The company positions itself as a science-driven partner for biotech firms, leveraging 16 years of collective experience in tech transfer and GMP production.

OncologyImmunology

Technology Platform

Integrated CDMO platform for biologics, offering end-to-end services from cell line development to commercial GMP manufacturing, with expertise in process development, analytics, and tech transfer for antibody-based therapeutics.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The growing global outsourcing trend in biologics manufacturing, especially from virtual and small biotechs, presents a significant growth opportunity.
Poland's strategic location in the EU, combined with a skilled workforce, offers a cost-competitive and high-quality alternative to Western European CDMOs.
Expansion into advanced therapeutic modalities (e.g., cell/gene therapy) could further diversify its service portfolio.

Risk Factors

Operational risk from batch failures or regulatory non-compliance could severely damage reputation.
High competition from large global CDMOs and dependence on the financial health of biotech clients create market vulnerability.
Geopolitical and economic instability in Europe could impact supply chains and operational costs.

Competitive Landscape

Rezon Bio competes in the crowded global biologics CDMO market against giants like Lonza, Fujifilm Diosynth, and Samsung Biologics, as well as other European players like Rentschler Biopharma. Its differentiation lies in its integrated Polish facilities, claimed operational excellence (95% batch success), and a focus on partnership, aiming to offer a more personalized and flexible service than larger competitors.

More companies in Biologics / Biosimilars →More companies in Poland →